Kūʻai pololei mai Kina Hale Hana CAS 1006376-62-0(1R,2R)-2-(3,4-difluorophenyl)cyclopropane carboxaMide Kūʻai wela

ʻO Ticagrelor kahi lāʻau antiplatelet waha, ʻo Brilinta kona inoa inoa ʻAmelika, a ʻo Brilique kona inoa inoa Europa. ʻO Ticagrelor kahi mea hoʻokae platelet adenosine diphosphate (ADP) receptor antagonist i hoʻolālā ʻia e pale i nā platelets mai ka hoʻopili pū ʻana a hana i nā clots koko e hiki ai ke alakaʻi i ka puʻuwai a me nā hahau. Ma ʻAmelika Hui Pū ʻIa, ua ʻae mua ʻia ka ticagrelor e ka FDA i Iulai 2011 no ka mālama ʻana i nā poʻe maʻi makua me ka maʻi maʻi coronary (ACS). Hōʻike ka ʻikepili maʻi i ʻoi aku ka maikaʻi o ka ticagrelor ma mua o clopidogrel i ka hōʻemi ʻana i ka make cardiovascular no ka liʻiliʻi o 12 mau mahina ma hope o kahi hanana ACS. Eia kekahi, ua hōʻemi pū ka ticagrelorChemicalbook i ka loaʻa ʻana o ka stent thrombosis (ST) i nā maʻi i loaʻa i nā stents e mālama i ka ACS. I Iune 2020, ua hoʻolaha ʻo AstraZeneca ua ʻae ka US Food and Drug Administration (FDA) i ka anticoagulant Brilinta (ticagrelor) no ka hoʻohana ʻana i nā poʻe maʻi me ka maʻi maʻi coronary artery kiʻekiʻe (CAD) e hōʻemi i ka hopena o ka hōʻeha puʻuwai mua. a i ʻole ka pilikia o ka hahau ʻana. I Nowemapa 2020, ua hoʻolaha ʻo AstraZeneca ua ʻae ka US Food and Drug Administration (FDA) i kahi hōʻailona hou no ka anticoagulant Brilinta (ticagrelor), i hui pū me ka aspirin, no ka mālama ʻana i ka ischemia acute. I nā poʻe maʻi me ka maʻi hemorrhagic a i ʻole transient ischemic attack (TIA), hoʻemi ia i ka hopena o ka hahau ma hope.